Abstract
Multi-drug resistance (MDR) is a significant barrier to effective chemotherapy of cancer. The induction of drug metabolizing enzymes (DMEs) and efflux transporters has been regarded as one of the major mechanisms of drug resistance. As a master transcription factor of DMEs and efflux transporters, pregnane X receptor (PXR), an orphan nuclear receptor known for its activation by structurally diverse compounds, is expressed in some cancer cells and tissues, and is implicated as a novel master regulator of MDR in cancers. This review describes recent publications and patents on the mechanism of PXR transcription, the expression of PXR in cancers, and its potential roles in cancer MDR. We also discuss the recent patents published to overcome PXR-mediated MDR and other potential roles of PXR in cancers.
Keywords: Multi-drug resistance, pregnane X receptor, Drug metabolism enzyme, Drug transporter, Cancer treatment, Nuclear receptor, Steroid X receptor, Inhibitor, Chemotherapeutics, Carcinogenesis, Cancer repressor
Recent Patents on Anti-Cancer Drug Discovery
Title: Pregnane X Receptor and its Potential Role in Drug Resistance in Cancer Treatment
Volume: 4 Issue: 1
Author(s): Yakun Chen and Daotai Nie
Affiliation:
Keywords: Multi-drug resistance, pregnane X receptor, Drug metabolism enzyme, Drug transporter, Cancer treatment, Nuclear receptor, Steroid X receptor, Inhibitor, Chemotherapeutics, Carcinogenesis, Cancer repressor
Abstract: Multi-drug resistance (MDR) is a significant barrier to effective chemotherapy of cancer. The induction of drug metabolizing enzymes (DMEs) and efflux transporters has been regarded as one of the major mechanisms of drug resistance. As a master transcription factor of DMEs and efflux transporters, pregnane X receptor (PXR), an orphan nuclear receptor known for its activation by structurally diverse compounds, is expressed in some cancer cells and tissues, and is implicated as a novel master regulator of MDR in cancers. This review describes recent publications and patents on the mechanism of PXR transcription, the expression of PXR in cancers, and its potential roles in cancer MDR. We also discuss the recent patents published to overcome PXR-mediated MDR and other potential roles of PXR in cancers.
Export Options
About this article
Cite this article as:
Chen Yakun and Nie Daotai, Pregnane X Receptor and its Potential Role in Drug Resistance in Cancer Treatment, Recent Patents on Anti-Cancer Drug Discovery 2009; 4 (1) . https://dx.doi.org/10.2174/157489209787002498
DOI https://dx.doi.org/10.2174/157489209787002498 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Epigenetic Regulators Governing Cancer Stem Cells and Epithelial- Mesenchymal Transition in Oral Squamous Cell Carcinoma
Current Stem Cell Research & Therapy Mechanisms of Drug Resistance in Cancer Chemotherapy: Coordinated Role and Regulation of Efflux Transporters and Metabolizing Enzymes
Current Pharmaceutical Design The mTOR Signaling Network: Insights from Its Role During Embryonic Development
Current Medicinal Chemistry CARING (CAncer Risk and INsulin analoGues): The Association of Diabetes Mellitus and Cancer Risk with Focus on Possible Determinants - A Systematic Review and a Meta-Analysis
Current Drug Safety Impact of Metformin on Male Reproduction
Current Pharmaceutical Design Promotion of Metastasis-associated Gene Expression in Survived PANC-1 Cells Following Trichostatin A Treatment
Anti-Cancer Agents in Medicinal Chemistry Loss of p27 Associated with Risk for Endometrial Carcinoma Arising in the Setting of Obesity
Current Molecular Medicine Cyclooxygenase-2 Inhibitors: A Painful Lesson
Cardiovascular & Hematological Disorders-Drug Targets Prolapsed Uterine Smooth Muscle Tumor of uncertain Malignant Potential: A Case Report and Review of Radiological Findings
Current Medical Imaging Micro Arrays and Biochips: Applications and Potential in Genomics and Proteomics
Current Genomics Targeting Tumor Lymphangiogenesis: An Update
Current Medicinal Chemistry Targeting the LKB1 Tumor Suppressor
Current Drug Targets Synthesis, Radiosynthesis and Metabolism of 131I-Y-c(CGRRAGGSC)
Anti-Cancer Agents in Medicinal Chemistry Development of Selective Cyclin-Dependent Kinase 4 Inhibitors for Antineoplastic Therapies
Anti-Cancer Agents in Medicinal Chemistry Diabetes, Cancer and Treatment – A Mini-Review
Current Drug Safety Harnessing the Tumor Suppressor Function of FOXO as an Alternative Therapeutic Approach in Cancer
Current Drug Targets Gestational Trophoblastic Neoplasia, an Ancient Disease: New Light and Potential Therapeutic Targets
Anti-Cancer Agents in Medicinal Chemistry Targeted Radionuclide Therapy - An Overview
Current Radiopharmaceuticals Scientific Papers and Patents on Substances with Unproven Effects. Part 2
Recent Patents on Drug Delivery & Formulation Matrix Metalloproteinases: New Routes to the Use of MT1-MMP As A Therapeutic Target in Angiogenesis-Related Disease
Current Pharmaceutical Design